Minerva Neurosciences, Inc (NERV)
Minerva Neurosciences, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for neuropsychiatric and neurological disorders. The company's pipeline includes treatments targeting conditions such as schizophrenia, cognitive impairment, and other central nervous system disorders. Minerva aims to address unmet medical needs through novel drug candidates and has a focus on advancing neuroscience research.
Company News
The schizophrenia market is expected to grow significantly by 2034, driven by rising disease prevalence, expanding approved therapies, and the anticipated launch of new treatments such as Olanzapine LAI, Iclepertin, Ulotaront, and Brilaroxazine.
Cartesian Therapeutics announced positive top-line results from its mid-stage study evaluating lead candidate Descartes-08 in patients with generalized myasthenia gravis. The study achieved its primary endpoint, with 71% of MG patients treated with Descartes-08 showing significant improvements in MG Composite score compared to 25% with placebo.
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index falling more than 100 points on Tuesday. The Dow traded down 0.35% to 38,932.26 while the NASDAQ rose 0.28% to 16,021.41. The S&P 500 also rose, gaining, 0.04% to 5,071.40. Check This Out: Wall Street's Most Accurate Analysts' Views On 3 Risk Off Stocks With Over 5% Dividend Yields  Leading and Lagging Sectors  Utilities shares rose by 1.2% on Tuesday. In trading on Tuesday, energy shares fell by 0.4%.  Top Headline  The J.M. Smucker Company (NYSE: SJM) posted better-than-expected earnings for its fourth quarter on Tuesday. The company reported third-quarter adjusted earnings per share of $2.48, beating the analyst consensus of $2.27. J.M. Smucker registered quarterly revenues of $2.229 billion, marginally beating the consensus estimate of $2.220 billion.  Equities Trading UP  Janux Therapeutics, Inc. (NASDAQ: JANX) shares shot up 191% to $44.00 after the company announced updated clinical data for both of its clinical programs. Shares of Hims & Hers Health, Inc. (NYSE: HIMS) got a boost, surging 32% to $13.50 after the company reported better-than-expected fourth-quarter financial results and issued strong guidance. Viking Therapeutics, Inc. ...
Penny stocks under $1 to watch this week. The post Hot Penny Stocks To Buy For Under $1 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.